

FOI REF: 25/266

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

9th May 2025

Tel: 0300 131 4500

Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

I would like to request data on the treatment of patients with hormone therapies for prostate cancer at your Trust for the period January 1, 2023- December 31, 2024.

For each of the following hormone therapies used to treat prostate cancer, please provide the number of patients treated at your Trust between 01 January and 31 December (by years 2023 and 2024). For each therapy, broken down the data into the following categories:

1. Total Number of Patients Treated for ICD-10 C61 / M1-M1c (metastatic)

2023 = 208

2024 = 252

2. Number of Patients for Whom Hormone Therapy Was Initiated for ICD-10 C61 / M1-M1c (metastatic)

3.

2023 = 78

2024 = 71

4. Number of Patients for Whom Hormone Therapy Was Continued; ICD-10 C61 / M1-M1c (metastatic)

2023 = 130

2024 = 181

5. Number of patients for whom docetaxel was initiated for ICD-10 C61 / M1-M1c (localised & metastatic)

2023 = 9 only metastatic

2024 = 2 only metastatic

Cont.../

The hormone therapies of interest are:

a)	ADT alone	0
b)	Abiraterone (Zytiga) in combination with any ADT	0
c)	Abiraterone (Zytiga) – no ADT	15
d)	Enzalutamide (Xtandi) in combination with any ADT	0
e)	Enzalutamide (Xtandi) – no ADT	303
f)	Apalutamide (Erleada) in combination with any ADT	0
g)	Darolutamide (Nubeqa) in combination with any ADT	0
h)	Darolutamide (Nubeqa) in combination with any ADT with docetaxel	0
i)	Docetaxel in combination with any ADT	0

Total number of patients in each year, for each therapy for whom:

•	Hormone therapy was initiated	71
•	Hormone therapy was continued	240
•	Docetaxel was initiated	7

I would appreciate it if you could provide the information in an electronic format, preferably in the attached spreadsheet format.

Please see the attached document – ‘FOI 25-266 - Updated Data Response (002)’.

Please note that East Sussex Healthcare NHS Trust does not usually supply any of the hormone parts of the treatment such as Goserelin, Leuprolode, Nilutamide and flutamide. These are usually supplied via the General Practitioners and are not included in our figures. We have therefore included all patients in the general lines where there was an option.

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust’s response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner’s Office
Wycliffe House
Water Lane
Wilmslow
Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Freedom of Information Department
esh-tr.foi@nhs.net

DRUG(S)	Total Number of Patients Treated for ICD-10 C61 / M0 and ICD-10 C61 / M1-M1c (localised & metastatic)			Number of Patients for Whom Hormone Therapy Was Initiated for ICD-10 C61 / M0 and ICD-10 C61 / M1-M1c (localised & metastatic)			Number of Patients for Whom Hormone Therapy Was Continued for ICD-10 C61 / M0 and ICD-10 C61 / M1-M1c (localised & metastatic)	
	Jan 1 2023-Dec 31 2023	Jan 1 2024-Dec 31 2024		Jan 1 2023-Dec 31 2023	Jan 1 2024-Dec 31 2024		Jan 1 2023-Dec 31 2023	Jan 1 2024-Dec 31 2024
Bicalutamide or Flutamide alone (ADT)	0	0		0	0		0	0
Abiraterone (Zytiga) in combination with any ADT	0	0		0	0		0	0
Abiraterone (Zytiga) – no ADT	3	12		3	7		0	5
Enzalutamide (Xtandi) in combination with any ADT	0	0		0	0		0	0
Enzalutamide (Xtandi) – no ADT	39	264		3	60		36	204
Apalutamide (Erleada) in combination with any ADT	0	0		0	0		0	0
Darolutamide (Nubeqa) in combination with any ADT	0	0		0	0		0	0
Darolutamide (Nubeqa) in combination with any ADT and docetaxel / cabazitaxel	0	0		0	0		0	0
A GnRH antagonist (degarelix, relugolix)	0	0		0	0		0	0
A GnRH agonist (gosereline, leuprorelin, triptorelin)	0	0		0	0		0	0